The genetics of adiponectin

Current Diabetes Reports

Volumn 3, Issue 2, 2003, Pages 151-158

  Vasseur, Francis ^a   Leprêtre, Frédéric ^a   Lacquemant, Corinne ^b   Froguel, Philippe ^a  

^a INSTITUT DE BIOLOGIE DE LILLE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADIPONECTIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN D; CALCIUM; CHEMOKINE; CYSTEINE PROTEINASE; CYTOKINE; FATTY ACID; GLUCOSE; GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN; HISTIDINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1; INTERLEUKIN RECEPTOR; KININOGEN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLATELET DERIVED GROWTH FACTOR; POTASSIUM; PROTEIN SERINE THREONINE KINASE; ROSIGLITAZONE; SCAVENGER RECEPTOR; SOMATOSTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; PROTEIN; SIGNAL PEPTIDE;

5' UNTRANSLATED REGION; ADIPOCYTE; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; CELLULAR DISTRIBUTION; CHROMOSOME 3Q; CORONARY ARTERY DISEASE; DATA ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; DRUG MECHANISM; ENERGY METABOLISM; ETHNOLOGY; EVIDENCE BASED MEDICINE; EXON; GENE LOCUS; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC VARIABILITY; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRON; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POINT MUTATION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ARTERIOSCLEROSIS; GENE DELETION; GENETICS;

ADIPONECTIN; ANIMALS; ARTERIOSCLEROSIS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; EXONS; GENE DELETION; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRONS; METABOLIC SYNDROME X; POINT MUTATION; PROTEINS; VARIATION (GENETICS);

EID: 0038545484     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0039-4     Document Type: Review

References (59)

1. Scherer PE, Williams S, Fogliano M, et al.: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
2. Maeda K, Okubo K, Shimomura I, et al.: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
3. Saito K, Tobe T, Minoshima S, et al.: Organization of the gene for gelatin-binding protein (GBP28). Gene 1999, 229:67-73.
4. Mori Y, Otabe S, Dina C, et al.: Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p. Diabetes 2002, 51:1247-1255.
5. Kissebah AH, Sonnenberg GE, Myklebust L et al.: Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A 2000, 97:14478-14483.
6. Vionnet N, Ham El H, Dupont S, et al.: Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000, 67:1470-1480.
7. Hotta K, Funahashi T, Arita Y, et al.: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
8. Lindsay RS, Funahashi T, Hanson RL, et al.: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360:57-58.
9. Arita Y, Kihara S, Ouchi N, et al.: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
10. Weyer C, Funahashi T, Tanaka S, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
11. Matsubara M, Maruoka S, Katayose S: Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002, 87:2764-2769.
12. Statnick MA, Beavers LS, Conner LJ et al.: Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 2000, 1:81-88.
13. Haque WA, Shimomura I, Matsuzawa Y, et al.: Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002,87:2395.
14. Yamauchi T, Kamon J, Waki H, et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
15. Fruebis J, Tsao TS, Javorschi S, et al.: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001, 98:2005-2010.
16. Maeda N, Shimomura I, Kishida K, et al.: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
17. Berliner JA, Navab M, Fogelman AM, et al.: Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995, 91:2488-2496.
18. Francke S, Manraj M, Lacquemant C, et al.: A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum Mol Genet 2001, 10:2751-2765.
19. Yokota T, Oritani K, Takahashi I, et al.: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723-1732.
20. Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
21. Ouchi N, Kihara S, Arita Y, et al.: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
22. Arita Y, Kihara S, Ouchi N, et al.: Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002, 105:2893-2898.
23. Matsuda M, Shimomura I, Sata M, et al.: Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002,277:37487-37491.
24. Comuzzie AG, Funahashi T, Sonnenberg G, et al.: The genetic basis of plasma variation in adiponectin, a global endophenotype for obesity and the metabolic syndrome. J Clin Endocrinol Metab 2001, 86:4321-4325.
25. Vasseur F, Helbecque N, Dina C, et al.: Single nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 2002, 11:2607-2614.
26. Takahashi M, Arita Y, Yamagata K, et al.: Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 2000, 24:861-868.
27. Hara K, Boutin P, Mori Y, et al.: Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002, 51:536-540.
28. Menzaghi C, Ercolino T, Di Paola R, et al.: A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002, 51:2306-2312.
29. Stumvoll M, Tschritter O, Fritsche A, et al.: Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 2002, 51:37-41.
30. Populaire C, Mori Y, Dina C, et al.: Does the -11377 promoter variant of APM1 gene contribute to the genetic risk for T2DM in Japanese families ? Diabetologia 2003, in press.
31. Cartegni L, Chew SL, Krainer AR: Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002, 3:285-298.
32. Uitterlinden AG, Burger H, Huang Q, et al.: Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med 1998, 338:1016-1021.
33. Horikawa Y, Oda N, Cox NJ, et al.: Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000, 26:163-175.
34. Schaffler A, Langmann T, Palitzsch KD, et al.: Identification and characterization of the human adipocyte apM-1 promoter. Biochim Biophys Acta 1998, 1399:187-197.
35. Maekawa T, Imamoto F, Merlino GT, et al.: Cooperative function of two separate enhancers of the human epidermal growth factor receptor proto-oncogene. J Biol Chem 1989, 264:5488-5494.
36. Kondo H, Shimomura I, Matsukawa Y, et al.: Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002, 51:2325-2328.
37. Shapiro L, Scherer PE: The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998, 8:335-338.
38. Sato C, Yasukawa Z, Honda N, et al.: Identification and adipocyte differentiation-dependent expression of the unique disialic acid residue in an adipose tissue-specific glycoprotein, adipo Q. J Biol Chem 2001, 276:28849-28856.
39. Wang Y, Xu A, Knight C, et al.: Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 2002, 277:19521-19529.
40. Kubota N, Terauchi Y, Yamauchi T, et al.: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002, 277:25863-25866.
41. Yang WS, Jeng CY, Wu TJ, et al.: Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002, 25:376-380.
42. Stumvoll M, Haring H: The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 2002, 51:2341-2347.
43. Hotta K, Funahashi T, Bodkin NL, et al.: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001, 50:1126-1133.
44. Stefan N, Vozarova B, Funahashi T, et al.: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002, 51:1884-1888.
45. Berg AH, Combs TP, Du X, et al.: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7:947-953.
46. Combs TP, Berg AH, Obici S, et al.: Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001, 108:1875-1881.
47. Lehto M, Tuomi T, Mahtani MM, et al.: Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect. J Clin Invest 1997, 99:582-591.
48. Rizzu P, Baldini A: Three members of the human cystatin gene superfamily, AHSG, HRG, and KNG, map within one megabase of genomic DNA at 3q27. Cytogenet Cell Genet 1995, 70:26-28.
49. Mather KJ, Paradisi G, Leaming R, et al.: Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity. Diabetes Metab Res Rev 2002, 18:118-126.
50. Strowski MZ, Parmar RM, Blake AD, et al.: Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 2000, 141:111-117.
51. Vijayaraghavan S, Hitman GA, Kopelman PG: Apolipoprotein-D polymorphism: a genetic marker for obesity and hyperinsulinemia. J Clin Endocrinol Metab 1994, 79:568-570.
52. Xu G, Marshall CA, Lin TA, et al.: Insulin mediates glucose-stimulated phosphorylation of PHAS-I by pancreatic beta cells. An insulin-receptor mechanism for autoregulation of protein synthesis by translation. J Biol Chem 1998, 273:4485-4491.
53. Yoshizawa F, Kimball SR, Jefferson LS: Modulation of translation initiation in rat skeletal muscle and liver in response to food intake. Biochem Biophys Res Commun 1997, 240:825-831.
54. Delepine M, Nicolino M, Barrett T, et al.: EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000, 25:406-409.
55. Tsukiyama-Kohara K, Poulin F, Kohara M, et al.: Adipose tissue reduction in mice lacking the translational inhibitor 4EBP1. Nat Med 2001, 7:1128-1132.
56. Wesche H, Korherr C, Kracht M, et al.: The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J Biol Chem 1997, 272:7727-7731.
57. Heitmeier MR, Arnush M, Scarim AL, et al.: Pancreatic beta-cell damage mediated by beta-cell production of interleukin-1. A novel mechanism for virus-induced diabetes. J Biol Chem 2001, 276:11151-11158.
58. Reich DE, Lander ES: On the allelic spectrum of human disease. Trends Genet 2001, 17:502-510.
59. Pritchard JK: Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 2001,69:124-137.